Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2008 May;7(5):426-37. doi: 10.1038/nrd2462.

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Author information

1
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA.

Abstract

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.

PMID:
18425072
PMCID:
PMC2715836
DOI:
10.1038/nrd2462
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center